nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Tacrolimus—atopic dermatitis	0.412	1	CrCtD
Pimecrolimus—MTOR—Tacrolimus—atopic dermatitis	0.122	0.504	CbGbCtD
Pimecrolimus—FKBP1A—Tacrolimus—atopic dermatitis	0.106	0.436	CbGbCtD
Pimecrolimus—Sirolimus—Tacrolimus—atopic dermatitis	0.0882	0.333	CrCrCtD
Pimecrolimus—Everolimus—Tacrolimus—atopic dermatitis	0.0882	0.333	CrCrCtD
Pimecrolimus—Temsirolimus—Tacrolimus—atopic dermatitis	0.0882	0.333	CrCrCtD
Pimecrolimus—CYP3A4—Tacrolimus—atopic dermatitis	0.00299	0.0124	CbGbCtD
Pimecrolimus—CYP3A4—Loratadine—atopic dermatitis	0.00219	0.00904	CbGbCtD
Pimecrolimus—CYP3A4—Methylprednisolone—atopic dermatitis	0.002	0.00827	CbGbCtD
Pimecrolimus—CYP3A4—Triamcinolone—atopic dermatitis	0.00152	0.00627	CbGbCtD
Pimecrolimus—CYP3A4—Betamethasone—atopic dermatitis	0.0013	0.00538	CbGbCtD
Pimecrolimus—CYP3A4—Prednisolone—atopic dermatitis	0.00129	0.00531	CbGbCtD
Pimecrolimus—CYP3A4—Hydrocortisone—atopic dermatitis	0.00122	0.00503	CbGbCtD
Pimecrolimus—CYP3A4—Prednisone—atopic dermatitis	0.00121	0.00501	CbGbCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CABIN1—atopic dermatitis	0.000981	0.057	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—TSLP—atopic dermatitis	0.000767	0.0446	CbGpPWpGaD
Pimecrolimus—CYP3A4—Dexamethasone—atopic dermatitis	0.000758	0.00313	CbGbCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL18R1—atopic dermatitis	0.000631	0.0367	CbGpPWpGaD
Pimecrolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CABIN1—atopic dermatitis	0.000596	0.0347	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—RELB—atopic dermatitis	0.000582	0.0338	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—RELB—atopic dermatitis	0.000513	0.0298	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—RELB—atopic dermatitis	0.000478	0.0278	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—FCER2—atopic dermatitis	0.00038	0.0221	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—atopic dermatitis	0.000357	0.0208	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—CCL11—atopic dermatitis	0.000337	0.0196	CbGpPWpGaD
Pimecrolimus—MTOR—SREBF and miR33 in cholesterol and lipid homeostasis—PPARA—atopic dermatitis	0.000288	0.0167	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—CCL11—atopic dermatitis	0.000284	0.0165	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—CCL17—atopic dermatitis	0.000282	0.0164	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—STAT6—atopic dermatitis	0.000267	0.0155	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—CXCR3—atopic dermatitis	0.00024	0.014	CbGpPWpGaD
Pimecrolimus—MTOR—FSH signaling pathway—BDNF—atopic dermatitis	0.000229	0.0133	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—CCL11—atopic dermatitis	0.000228	0.0132	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—STAT6—atopic dermatitis	0.00022	0.0128	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—CASP1—atopic dermatitis	0.000217	0.0126	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—atopic dermatitis	0.000216	0.0126	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—STAT6—atopic dermatitis	0.000214	0.0124	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—CXCL10—atopic dermatitis	0.000194	0.0113	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—atopic dermatitis	0.000192	0.0112	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FCER1A—atopic dermatitis	0.000164	0.00954	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL5—atopic dermatitis	0.000154	0.00894	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MS4A2—atopic dermatitis	0.000153	0.00887	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CXCL10—atopic dermatitis	0.000139	0.0081	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—atopic dermatitis	0.000131	0.00763	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—BDNF—atopic dermatitis	0.000125	0.00728	CbGpPWpGaD
Pimecrolimus—MTOR—Type II diabetes mellitus—MAPK8—atopic dermatitis	0.000124	0.0072	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—CMA1—atopic dermatitis	0.000118	0.00686	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—KIF3A—atopic dermatitis	0.000118	0.00685	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL4—atopic dermatitis	0.000116	0.00676	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL18—atopic dermatitis	0.000116	0.00674	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD8A—atopic dermatitis	0.000114	0.00664	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL10—atopic dermatitis	0.000112	0.00654	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL4—atopic dermatitis	0.000112	0.00653	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL4—atopic dermatitis	0.000109	0.00636	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—NFKBIA—atopic dermatitis	0.000108	0.00625	CbGpPWpGaD
Pimecrolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—MAPK8—atopic dermatitis	0.000107	0.00624	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CCR5—atopic dermatitis	0.000104	0.00607	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—STAT6—atopic dermatitis	9.97e-05	0.0058	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CTSE—atopic dermatitis	9.91e-05	0.00576	CbGpPWpGaD
Pimecrolimus—MTOR—Type II diabetes mellitus—TNF—atopic dermatitis	9.8e-05	0.0057	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—NFKBIA—atopic dermatitis	9.48e-05	0.00552	CbGpPWpGaD
Pimecrolimus—MTOR—neck—atopic dermatitis	9.46e-05	0.254	CbGeAlD
Pimecrolimus—MTOR—Cellular responses to stress—CABIN1—atopic dermatitis	9.42e-05	0.00548	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CARD11—atopic dermatitis	9.42e-05	0.00548	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—STAT6—atopic dermatitis	9.04e-05	0.00526	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CARD11—atopic dermatitis	8.99e-05	0.00523	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—atopic dermatitis	8.88e-05	0.00516	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—IFNG—atopic dermatitis	8.86e-05	0.00515	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	8.51e-05	0.00495	CbGpPWpGaD
Pimecrolimus—FKBP1A—neck—atopic dermatitis	8.51e-05	0.229	CbGeAlD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—atopic dermatitis	8.5e-05	0.00494	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CARD11—atopic dermatitis	8.32e-05	0.00484	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—NFKBIA—atopic dermatitis	8.3e-05	0.00483	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—IL1B—atopic dermatitis	7.9e-05	0.00459	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—CXCL8—atopic dermatitis	7.67e-05	0.00446	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—MAPK8—atopic dermatitis	7.53e-05	0.00438	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—NGF—atopic dermatitis	7.07e-05	0.00411	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IFNG—atopic dermatitis	7.02e-05	0.00408	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IFNG—atopic dermatitis	6.79e-05	0.00395	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—MAPK8—atopic dermatitis	6.75e-05	0.00392	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—atopic dermatitis	6.55e-05	0.00381	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CXCL8—atopic dermatitis	6.53e-05	0.0038	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FCER1A—atopic dermatitis	6.38e-05	0.00371	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL1B—atopic dermatitis	6.26e-05	0.00364	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL2—atopic dermatitis	6.24e-05	0.00363	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	6.23e-05	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—MAPK8—atopic dermatitis	6.22e-05	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—IFNG—atopic dermatitis	6.14e-05	0.00357	CbGpPWpGaD
Pimecrolimus—MTOR—skin of body—atopic dermatitis	6.12e-05	0.165	CbGeAlD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL1B—atopic dermatitis	6.05e-05	0.00352	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—MAPK8—atopic dermatitis	6.04e-05	0.00351	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL2—atopic dermatitis	6.03e-05	0.00351	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTSE—atopic dermatitis	6.01e-05	0.0035	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—BDNF—atopic dermatitis	6e-05	0.00349	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—MAPK8—atopic dermatitis	5.95e-05	0.00346	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—MAPK8—atopic dermatitis	5.95e-05	0.00346	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—atopic dermatitis	5.93e-05	0.00345	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MS4A2—atopic dermatitis	5.93e-05	0.00345	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	5.62e-05	0.00327	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CD79A—atopic dermatitis	5.51e-05	0.00321	CbGpPWpGaD
Pimecrolimus—FKBP1A—skin of body—atopic dermatitis	5.51e-05	0.148	CbGeAlD
Pimecrolimus—MTOR—Regulation of Telomerase—IL2—atopic dermatitis	5.46e-05	0.00317	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—NGF—atopic dermatitis	5.33e-05	0.0031	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—DEFB1—atopic dermatitis	5.28e-05	0.00307	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—MAPK8—atopic dermatitis	5.21e-05	0.00303	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—IL1B—atopic dermatitis	5.06e-05	0.00294	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—atopic dermatitis	5.01e-05	0.00291	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—MAPK8—atopic dermatitis	4.91e-05	0.00285	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—GLB1—atopic dermatitis	4.82e-05	0.0028	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—atopic dermatitis	4.71e-05	0.00274	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—MAPK8—atopic dermatitis	4.64e-05	0.0027	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—atopic dermatitis	4.55e-05	0.00264	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MAPK8—atopic dermatitis	4.41e-05	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—NFKBIA—atopic dermatitis	4.39e-05	0.00255	CbGpPWpGaD
Pimecrolimus—Erythema—Tacrolimus—atopic dermatitis	4.39e-05	0.000697	CcSEcCtD
Pimecrolimus—Malnutrition—Tacrolimus—atopic dermatitis	4.39e-05	0.000697	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—atopic dermatitis	4.34e-05	0.00252	CbGpPWpGaD
Pimecrolimus—Vomiting—Diphenhydramine—atopic dermatitis	4.33e-05	0.000688	CcSEcCtD
Pimecrolimus—Vomiting—Dimenhydrinate—atopic dermatitis	4.33e-05	0.000688	CcSEcCtD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—atopic dermatitis	4.31e-05	0.00251	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Fluocinolone Acetonide—atopic dermatitis	4.3e-05	0.000682	CcSEcCtD
Pimecrolimus—Rash—Dimenhydrinate—atopic dermatitis	4.29e-05	0.000682	CcSEcCtD
Pimecrolimus—Rash—Diphenhydramine—atopic dermatitis	4.29e-05	0.000682	CcSEcCtD
Pimecrolimus—Dermatitis—Diphenhydramine—atopic dermatitis	4.29e-05	0.000682	CcSEcCtD
Pimecrolimus—Dermatitis—Dimenhydrinate—atopic dermatitis	4.29e-05	0.000682	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Loratadine—atopic dermatitis	4.29e-05	0.000681	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—FCER2—atopic dermatitis	4.27e-05	0.00248	CbGpPWpGaD
Pimecrolimus—Headache—Dimenhydrinate—atopic dermatitis	4.27e-05	0.000678	CcSEcCtD
Pimecrolimus—Headache—Diphenhydramine—atopic dermatitis	4.27e-05	0.000678	CcSEcCtD
Pimecrolimus—Back pain—Tacrolimus—atopic dermatitis	4.25e-05	0.000675	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—MAPK8—atopic dermatitis	4.24e-05	0.00247	CbGpPWpGaD
Pimecrolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	4.18e-05	0.00243	CbGpPWpGaD
Pimecrolimus—Abdominal pain upper—Hydrocortisone—atopic dermatitis	4.15e-05	0.00066	CcSEcCtD
Pimecrolimus—Abdominal pain—Loratadine—atopic dermatitis	4.15e-05	0.000659	CcSEcCtD
Pimecrolimus—Body temperature increased—Loratadine—atopic dermatitis	4.15e-05	0.000659	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mometasone—atopic dermatitis	4.1e-05	0.000652	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Fluocinolone Acetonide—atopic dermatitis	4.07e-05	0.000647	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—KIF3A—atopic dermatitis	4.06e-05	0.00236	CbGpPWpGaD
Pimecrolimus—Nausea—Dimenhydrinate—atopic dermatitis	4.05e-05	0.000643	CcSEcCtD
Pimecrolimus—Nausea—Diphenhydramine—atopic dermatitis	4.05e-05	0.000643	CcSEcCtD
Pimecrolimus—Paraesthesia—Mometasone—atopic dermatitis	4.04e-05	0.000642	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—atopic dermatitis	4.03e-05	0.00234	CbGpPWpGaD
Pimecrolimus—Pain—Fluocinolone Acetonide—atopic dermatitis	4.03e-05	0.00064	CcSEcCtD
Pimecrolimus—Dyspnoea—Mometasone—atopic dermatitis	4.01e-05	0.000638	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NGF—atopic dermatitis	4e-05	0.00233	CbGpPWpGaD
Pimecrolimus—MTOR—head—atopic dermatitis	3.99e-05	0.107	CbGeAlD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL22—atopic dermatitis	3.97e-05	0.00231	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.91e-05	0.00227	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—atopic dermatitis	3.9e-05	0.00227	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—atopic dermatitis	3.87e-05	0.00225	CbGpPWpGaD
Pimecrolimus—Breast disorder—Methylprednisolone—atopic dermatitis	3.86e-05	0.000613	CcSEcCtD
Pimecrolimus—Pain—Mometasone—atopic dermatitis	3.85e-05	0.000612	CcSEcCtD
Pimecrolimus—Cough—Tacrolimus—atopic dermatitis	3.83e-05	0.000609	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CASP8—atopic dermatitis	3.81e-05	0.00222	CbGpPWpGaD
Pimecrolimus—Arthralgia—Tacrolimus—atopic dermatitis	3.74e-05	0.000594	CcSEcCtD
Pimecrolimus—Body temperature increased—Fluocinolone Acetonide—atopic dermatitis	3.73e-05	0.000592	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKBIA—atopic dermatitis	3.72e-05	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FCER1A—atopic dermatitis	3.71e-05	0.00216	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Tacrolimus—atopic dermatitis	3.71e-05	0.00059	CcSEcCtD
Pimecrolimus—Influenza—Triamcinolone—atopic dermatitis	3.7e-05	0.000588	CcSEcCtD
Pimecrolimus—Asthma—Triamcinolone—atopic dermatitis	3.7e-05	0.000588	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mometasone—atopic dermatitis	3.68e-05	0.000585	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—atopic dermatitis	3.67e-05	0.00213	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Hydrocortisone—atopic dermatitis	3.65e-05	0.00058	CcSEcCtD
Pimecrolimus—FKBP1A—head—atopic dermatitis	3.59e-05	0.0966	CbGeAlD
Pimecrolimus—MTOR—Innate Immune System—STAT6—atopic dermatitis	3.59e-05	0.00209	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Loratadine—atopic dermatitis	3.59e-05	0.00057	CcSEcCtD
Pimecrolimus—Oedema—Tacrolimus—atopic dermatitis	3.58e-05	0.000569	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Tacrolimus—atopic dermatitis	3.58e-05	0.000569	CcSEcCtD
Pimecrolimus—Infection—Tacrolimus—atopic dermatitis	3.56e-05	0.000565	CcSEcCtD
Pimecrolimus—Bronchitis—Triamcinolone—atopic dermatitis	3.56e-05	0.000565	CcSEcCtD
Pimecrolimus—Body temperature increased—Mometasone—atopic dermatitis	3.56e-05	0.000565	CcSEcCtD
Pimecrolimus—Abdominal pain—Mometasone—atopic dermatitis	3.56e-05	0.000565	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—MAPK8—atopic dermatitis	3.55e-05	0.00206	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL27—atopic dermatitis	3.54e-05	0.00206	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Tacrolimus—atopic dermatitis	3.51e-05	0.000558	CcSEcCtD
Pimecrolimus—Infestation—Hydrocortisone—atopic dermatitis	3.5e-05	0.000557	CcSEcCtD
Pimecrolimus—Infestation NOS—Hydrocortisone—atopic dermatitis	3.5e-05	0.000557	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—CARD11—atopic dermatitis	3.49e-05	0.00203	CbGpPWpGaD
Pimecrolimus—Conjunctivitis—Prednisolone—atopic dermatitis	3.49e-05	0.000554	CcSEcCtD
Pimecrolimus—Skin disorder—Tacrolimus—atopic dermatitis	3.48e-05	0.000553	CcSEcCtD
Pimecrolimus—Hypersensitivity—Fluocinolone Acetonide—atopic dermatitis	3.47e-05	0.000552	CcSEcCtD
Pimecrolimus—MTOR—Immune System—MS4A2—atopic dermatitis	3.45e-05	0.00201	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—NFKBIA—atopic dermatitis	3.45e-05	0.002	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Triamcinolone—atopic dermatitis	3.44e-05	0.000546	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CARD11—atopic dermatitis	3.36e-05	0.00195	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—atopic dermatitis	3.36e-05	0.00195	CbGpPWpGaD
Pimecrolimus—Pruritus—Fluocinolone Acetonide—atopic dermatitis	3.34e-05	0.00053	CcSEcCtD
Pimecrolimus—Vomiting—Loratadine—atopic dermatitis	3.34e-05	0.00053	CcSEcCtD
Pimecrolimus—Rash—Loratadine—atopic dermatitis	3.31e-05	0.000525	CcSEcCtD
Pimecrolimus—Dermatitis—Loratadine—atopic dermatitis	3.3e-05	0.000525	CcSEcCtD
Pimecrolimus—Infestation—Methylprednisolone—atopic dermatitis	3.29e-05	0.000523	CcSEcCtD
Pimecrolimus—Infestation NOS—Methylprednisolone—atopic dermatitis	3.29e-05	0.000523	CcSEcCtD
Pimecrolimus—Headache—Loratadine—atopic dermatitis	3.29e-05	0.000522	CcSEcCtD
Pimecrolimus—Face oedema—Prednisone—atopic dermatitis	3.27e-05	0.000519	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Tacrolimus—atopic dermatitis	3.26e-05	0.000519	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—SLC11A1—atopic dermatitis	3.23e-05	0.00188	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	3.23e-05	0.000512	CcSEcCtD
Pimecrolimus—Paraesthesia—Tacrolimus—atopic dermatitis	3.22e-05	0.000511	CcSEcCtD
Pimecrolimus—Conjunctivitis—Triamcinolone—atopic dermatitis	3.21e-05	0.00051	CcSEcCtD
Pimecrolimus—Dyspnoea—Tacrolimus—atopic dermatitis	3.19e-05	0.000507	CcSEcCtD
Pimecrolimus—Pruritus—Mometasone—atopic dermatitis	3.18e-05	0.000506	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL17—atopic dermatitis	3.17e-05	0.00185	CbGpPWpGaD
Pimecrolimus—Nausea—Loratadine—atopic dermatitis	3.12e-05	0.000495	CcSEcCtD
Pimecrolimus—Epistaxis—Triamcinolone—atopic dermatitis	3.11e-05	0.000494	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	3.09e-05	0.000491	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	3.09e-05	0.0018	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Mometasone—atopic dermatitis	3.08e-05	0.000489	CcSEcCtD
Pimecrolimus—MTOR—Immune System—DEFB1—atopic dermatitis	3.08e-05	0.00179	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NGF—atopic dermatitis	3.08e-05	0.00179	CbGpPWpGaD
Pimecrolimus—Pain—Tacrolimus—atopic dermatitis	3.06e-05	0.000487	CcSEcCtD
Pimecrolimus—Constipation—Tacrolimus—atopic dermatitis	3.06e-05	0.000487	CcSEcCtD
Pimecrolimus—Vomiting—Fluocinolone Acetonide—atopic dermatitis	3e-05	0.000476	CcSEcCtD
Pimecrolimus—Rash—Fluocinolone Acetonide—atopic dermatitis	2.97e-05	0.000472	CcSEcCtD
Pimecrolimus—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	2.97e-05	0.000472	CcSEcCtD
Pimecrolimus—Rhinitis—Triamcinolone—atopic dermatitis	2.97e-05	0.000472	CcSEcCtD
Pimecrolimus—Rhinitis—Methylprednisolone—atopic dermatitis	2.96e-05	0.000471	CcSEcCtD
Pimecrolimus—Headache—Fluocinolone Acetonide—atopic dermatitis	2.95e-05	0.000469	CcSEcCtD
Pimecrolimus—Pharyngitis—Triamcinolone—atopic dermatitis	2.94e-05	0.000467	CcSEcCtD
Pimecrolimus—Eye disorder—Hydrocortisone—atopic dermatitis	2.94e-05	0.000467	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Tacrolimus—atopic dermatitis	2.93e-05	0.000465	CcSEcCtD
Pimecrolimus—Conjunctivitis—Betamethasone—atopic dermatitis	2.91e-05	0.000462	CcSEcCtD
Pimecrolimus—Conjunctivitis—Dexamethasone—atopic dermatitis	2.91e-05	0.000462	CcSEcCtD
Pimecrolimus—Vomiting—Mometasone—atopic dermatitis	2.86e-05	0.000455	CcSEcCtD
Pimecrolimus—Urticaria—Tacrolimus—atopic dermatitis	2.85e-05	0.000452	CcSEcCtD
Pimecrolimus—Immune system disorder—Hydrocortisone—atopic dermatitis	2.84e-05	0.000451	CcSEcCtD
Pimecrolimus—Rash—Mometasone—atopic dermatitis	2.84e-05	0.000451	CcSEcCtD
Pimecrolimus—Dermatitis—Mometasone—atopic dermatitis	2.84e-05	0.00045	CcSEcCtD
Pimecrolimus—Body temperature increased—Tacrolimus—atopic dermatitis	2.83e-05	0.00045	CcSEcCtD
Pimecrolimus—Abdominal pain—Tacrolimus—atopic dermatitis	2.83e-05	0.00045	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—KIF3A—atopic dermatitis	2.83e-05	0.00164	CbGpPWpGaD
Pimecrolimus—Headache—Mometasone—atopic dermatitis	2.82e-05	0.000448	CcSEcCtD
Pimecrolimus—Erythema—Prednisolone—atopic dermatitis	2.8e-05	0.000445	CcSEcCtD
Pimecrolimus—Nausea—Fluocinolone Acetonide—atopic dermatitis	2.8e-05	0.000445	CcSEcCtD
Pimecrolimus—Eye disorder—Methylprednisolone—atopic dermatitis	2.76e-05	0.000439	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—MAPK8—atopic dermatitis	2.75e-05	0.0016	CbGpPWpGaD
Pimecrolimus—Erythema—Hydrocortisone—atopic dermatitis	2.74e-05	0.000435	CcSEcCtD
Pimecrolimus—Malnutrition—Hydrocortisone—atopic dermatitis	2.74e-05	0.000435	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—CASP1—atopic dermatitis	2.72e-05	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GLB1—atopic dermatitis	2.71e-05	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—atopic dermatitis	2.68e-05	0.00156	CbGpPWpGaD
Pimecrolimus—Nausea—Mometasone—atopic dermatitis	2.67e-05	0.000425	CcSEcCtD
Pimecrolimus—Immune system disorder—Methylprednisolone—atopic dermatitis	2.67e-05	0.000424	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methylprednisolone—atopic dermatitis	2.66e-05	0.000423	CcSEcCtD
Pimecrolimus—Hypersensitivity—Tacrolimus—atopic dermatitis	2.64e-05	0.000419	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events—IL6—atopic dermatitis	2.61e-05	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—atopic dermatitis	2.59e-05	0.0015	CbGpPWpGaD
Pimecrolimus—Erythema—Triamcinolone—atopic dermatitis	2.58e-05	0.00041	CcSEcCtD
Pimecrolimus—Erythema—Methylprednisolone—atopic dermatitis	2.57e-05	0.000409	CcSEcCtD
Pimecrolimus—Malnutrition—Methylprednisolone—atopic dermatitis	2.57e-05	0.000409	CcSEcCtD
Pimecrolimus—Angioedema—Prednisolone—atopic dermatitis	2.56e-05	0.000407	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CMA1—atopic dermatitis	2.56e-05	0.00149	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL11—atopic dermatitis	2.56e-05	0.00149	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NFKBIA—atopic dermatitis	2.54e-05	0.00148	CbGpPWpGaD
Pimecrolimus—Pruritus—Tacrolimus—atopic dermatitis	2.53e-05	0.000403	CcSEcCtD
Pimecrolimus—MTOR—Insulin Signaling—MAPK8—atopic dermatitis	2.53e-05	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—atopic dermatitis	2.52e-05	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—atopic dermatitis	2.52e-05	0.00146	CbGpPWpGaD
Pimecrolimus—Eye disorder—Dexamethasone—atopic dermatitis	2.51e-05	0.000399	CcSEcCtD
Pimecrolimus—Eye disorder—Betamethasone—atopic dermatitis	2.51e-05	0.000399	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK8—atopic dermatitis	2.51e-05	0.00146	CbGpPWpGaD
Pimecrolimus—Angioedema—Hydrocortisone—atopic dermatitis	2.5e-05	0.000398	CcSEcCtD
Pimecrolimus—Back pain—Triamcinolone—atopic dermatitis	2.49e-05	0.000396	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—TLR2—atopic dermatitis	2.46e-05	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIF3A—atopic dermatitis	2.46e-05	0.00143	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Tacrolimus—atopic dermatitis	2.45e-05	0.000389	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT6—atopic dermatitis	2.41e-05	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FCER2—atopic dermatitis	2.4e-05	0.0014	CbGpPWpGaD
Pimecrolimus—Angioedema—Triamcinolone—atopic dermatitis	2.36e-05	0.000374	CcSEcCtD
Pimecrolimus—Angioedema—Methylprednisolone—atopic dermatitis	2.35e-05	0.000373	CcSEcCtD
Pimecrolimus—Erythema—Betamethasone—atopic dermatitis	2.34e-05	0.000372	CcSEcCtD
Pimecrolimus—Erythema—Dexamethasone—atopic dermatitis	2.34e-05	0.000372	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	2.34e-05	0.00136	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	2.32e-05	0.000368	CcSEcCtD
Pimecrolimus—Oedema—Prednisolone—atopic dermatitis	2.29e-05	0.000364	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisolone—atopic dermatitis	2.29e-05	0.000364	CcSEcCtD
Pimecrolimus—Vomiting—Tacrolimus—atopic dermatitis	2.28e-05	0.000362	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	2.27e-05	0.00132	CbGpPWpGaD
Pimecrolimus—Rash—Tacrolimus—atopic dermatitis	2.26e-05	0.000359	CcSEcCtD
Pimecrolimus—Dermatitis—Tacrolimus—atopic dermatitis	2.26e-05	0.000359	CcSEcCtD
Pimecrolimus—Cough—Triamcinolone—atopic dermatitis	2.25e-05	0.000357	CcSEcCtD
Pimecrolimus—Headache—Tacrolimus—atopic dermatitis	2.24e-05	0.000357	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Hydrocortisone—atopic dermatitis	2.24e-05	0.000355	CcSEcCtD
Pimecrolimus—Oedema—Hydrocortisone—atopic dermatitis	2.24e-05	0.000355	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—CCL22—atopic dermatitis	2.23e-05	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—atopic dermatitis	2.23e-05	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD79A—atopic dermatitis	2.22e-05	0.00129	CbGpPWpGaD
Pimecrolimus—Infection—Hydrocortisone—atopic dermatitis	2.22e-05	0.000353	CcSEcCtD
Pimecrolimus—Nervous system disorder—Hydrocortisone—atopic dermatitis	2.19e-05	0.000348	CcSEcCtD
Pimecrolimus—Arthralgia—Methylprednisolone—atopic dermatitis	2.19e-05	0.000348	CcSEcCtD
Pimecrolimus—Eye disorder—Prednisone—atopic dermatitis	2.19e-05	0.000348	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	2.18e-05	0.000346	CcSEcCtD
Pimecrolimus—Flushing—Prednisone—atopic dermatitis	2.17e-05	0.000345	CcSEcCtD
Pimecrolimus—Skin disorder—Hydrocortisone—atopic dermatitis	2.17e-05	0.000345	CcSEcCtD
Pimecrolimus—Angioedema—Dexamethasone—atopic dermatitis	2.14e-05	0.00034	CcSEcCtD
Pimecrolimus—Angioedema—Betamethasone—atopic dermatitis	2.14e-05	0.00034	CcSEcCtD
Pimecrolimus—Nausea—Tacrolimus—atopic dermatitis	2.13e-05	0.000338	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—atopic dermatitis	2.11e-05	0.000336	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—atopic dermatitis	2.11e-05	0.00122	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Triamcinolone—atopic dermatitis	2.1e-05	0.000334	CcSEcCtD
Pimecrolimus—Oedema—Triamcinolone—atopic dermatitis	2.1e-05	0.000334	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methylprednisolone—atopic dermatitis	2.1e-05	0.000334	CcSEcCtD
Pimecrolimus—MTOR—Immune System—STAT6—atopic dermatitis	2.09e-05	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—atopic dermatitis	2.09e-05	0.00122	CbGpPWpGaD
Pimecrolimus—Infection—Triamcinolone—atopic dermatitis	2.09e-05	0.000332	CcSEcCtD
Pimecrolimus—Infection—Methylprednisolone—atopic dermatitis	2.09e-05	0.000331	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR3—atopic dermatitis	2.09e-05	0.00121	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Methylprednisolone—atopic dermatitis	2.06e-05	0.000327	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisolone—atopic dermatitis	2.05e-05	0.000326	CcSEcCtD
Pimecrolimus—Skin disorder—Methylprednisolone—atopic dermatitis	2.04e-05	0.000324	CcSEcCtD
Pimecrolimus—Erythema—Prednisone—atopic dermatitis	2.04e-05	0.000324	CcSEcCtD
Pimecrolimus—Malnutrition—Prednisone—atopic dermatitis	2.04e-05	0.000324	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	2.04e-05	0.000323	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CARD11—atopic dermatitis	2.04e-05	0.00118	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Hydrocortisone—atopic dermatitis	2.01e-05	0.000319	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—CCL27—atopic dermatitis	1.99e-05	0.00116	CbGpPWpGaD
Pimecrolimus—Pain—Prednisolone—atopic dermatitis	1.96e-05	0.000311	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	1.93e-05	0.000307	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—CXCL8—atopic dermatitis	1.93e-05	0.00112	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	1.92e-05	0.000305	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	1.91e-05	0.000304	CcSEcCtD
Pimecrolimus—Pain—Hydrocortisone—atopic dermatitis	1.91e-05	0.000304	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Betamethasone—atopic dermatitis	1.91e-05	0.000303	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Dexamethasone—atopic dermatitis	1.91e-05	0.000303	CcSEcCtD
Pimecrolimus—Oedema—Dexamethasone—atopic dermatitis	1.91e-05	0.000303	CcSEcCtD
Pimecrolimus—Oedema—Betamethasone—atopic dermatitis	1.91e-05	0.000303	CcSEcCtD
Pimecrolimus—Infection—Dexamethasone—atopic dermatitis	1.9e-05	0.000301	CcSEcCtD
Pimecrolimus—Infection—Betamethasone—atopic dermatitis	1.9e-05	0.000301	CcSEcCtD
Pimecrolimus—Paraesthesia—Triamcinolone—atopic dermatitis	1.89e-05	0.0003	CcSEcCtD
Pimecrolimus—Paraesthesia—Methylprednisolone—atopic dermatitis	1.89e-05	0.0003	CcSEcCtD
Pimecrolimus—Dyspnoea—Triamcinolone—atopic dermatitis	1.88e-05	0.000298	CcSEcCtD
Pimecrolimus—Nervous system disorder—Dexamethasone—atopic dermatitis	1.87e-05	0.000297	CcSEcCtD
Pimecrolimus—Nervous system disorder—Betamethasone—atopic dermatitis	1.87e-05	0.000297	CcSEcCtD
Pimecrolimus—Angioedema—Prednisone—atopic dermatitis	1.86e-05	0.000296	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—TAC1—atopic dermatitis	1.86e-05	0.00108	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NPS—atopic dermatitis	1.86e-05	0.00108	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	1.83e-05	0.00029	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCR3—atopic dermatitis	1.82e-05	0.00106	CbGpPWpGaD
Pimecrolimus—Urticaria—Prednisolone—atopic dermatitis	1.82e-05	0.000289	CcSEcCtD
Pimecrolimus—MTOR—Disease—SLC11A1—atopic dermatitis	1.82e-05	0.00106	CbGpPWpGaD
Pimecrolimus—Pain—Triamcinolone—atopic dermatitis	1.8e-05	0.000286	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—atopic dermatitis	1.79e-05	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—atopic dermatitis	1.79e-05	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL17—atopic dermatitis	1.78e-05	0.00104	CbGpPWpGaD
Pimecrolimus—Urticaria—Hydrocortisone—atopic dermatitis	1.78e-05	0.000282	CcSEcCtD
Pimecrolimus—Body temperature increased—Hydrocortisone—atopic dermatitis	1.77e-05	0.000281	CcSEcCtD
Pimecrolimus—Abdominal pain—Hydrocortisone—atopic dermatitis	1.77e-05	0.000281	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	1.74e-05	0.000276	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	1.74e-05	0.000276	CcSEcCtD
Pimecrolimus—Arthralgia—Prednisone—atopic dermatitis	1.73e-05	0.000276	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—IL5—atopic dermatitis	1.73e-05	0.001	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	1.72e-05	0.000274	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	1.72e-05	0.000273	CcSEcCtD
Pimecrolimus—Paraesthesia—Betamethasone—atopic dermatitis	1.71e-05	0.000272	CcSEcCtD
Pimecrolimus—Paraesthesia—Dexamethasone—atopic dermatitis	1.71e-05	0.000272	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—atopic dermatitis	1.71e-05	0.000995	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK8—atopic dermatitis	1.7e-05	0.000986	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Prednisolone—atopic dermatitis	1.69e-05	0.000268	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—atopic dermatitis	1.68e-05	0.00098	CbGpPWpGaD
Pimecrolimus—Urticaria—Triamcinolone—atopic dermatitis	1.67e-05	0.000266	CcSEcCtD
Pimecrolimus—Urticaria—Methylprednisolone—atopic dermatitis	1.67e-05	0.000265	CcSEcCtD
Pimecrolimus—Body temperature increased—Triamcinolone—atopic dermatitis	1.66e-05	0.000264	CcSEcCtD
Pimecrolimus—Oedema—Prednisone—atopic dermatitis	1.66e-05	0.000264	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—atopic dermatitis	1.66e-05	0.000264	CcSEcCtD
Pimecrolimus—Abdominal pain—Methylprednisolone—atopic dermatitis	1.66e-05	0.000264	CcSEcCtD
Pimecrolimus—Infection—Prednisone—atopic dermatitis	1.65e-05	0.000262	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	1.65e-05	0.000262	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Betamethasone—atopic dermatitis	1.65e-05	0.000262	CcSEcCtD
Pimecrolimus—Hypersensitivity—Hydrocortisone—atopic dermatitis	1.65e-05	0.000262	CcSEcCtD
Pimecrolimus—Pain—Betamethasone—atopic dermatitis	1.63e-05	0.000259	CcSEcCtD
Pimecrolimus—Pain—Dexamethasone—atopic dermatitis	1.63e-05	0.000259	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—CCR5—atopic dermatitis	1.63e-05	0.000949	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Prednisone—atopic dermatitis	1.63e-05	0.000259	CcSEcCtD
Pimecrolimus—Skin disorder—Prednisone—atopic dermatitis	1.62e-05	0.000257	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—atopic dermatitis	1.61e-05	0.000936	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—atopic dermatitis	1.6e-05	0.000931	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—atopic dermatitis	1.59e-05	0.000926	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK8—atopic dermatitis	1.59e-05	0.000925	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIF3A—atopic dermatitis	1.59e-05	0.000925	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP1—atopic dermatitis	1.59e-05	0.000922	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—atopic dermatitis	1.59e-05	0.000922	CbGpPWpGaD
Pimecrolimus—Pruritus—Hydrocortisone—atopic dermatitis	1.58e-05	0.000251	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dexamethasone—atopic dermatitis	1.56e-05	0.000248	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Betamethasone—atopic dermatitis	1.56e-05	0.000248	CcSEcCtD
Pimecrolimus—Hypersensitivity—Triamcinolone—atopic dermatitis	1.55e-05	0.000246	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methylprednisolone—atopic dermatitis	1.55e-05	0.000246	CcSEcCtD
Pimecrolimus—Diarrhoea—Hydrocortisone—atopic dermatitis	1.53e-05	0.000243	CcSEcCtD
Pimecrolimus—Urticaria—Betamethasone—atopic dermatitis	1.52e-05	0.000241	CcSEcCtD
Pimecrolimus—Urticaria—Dexamethasone—atopic dermatitis	1.52e-05	0.000241	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—atopic dermatitis	1.52e-05	0.000241	CcSEcCtD
Pimecrolimus—Body temperature increased—Betamethasone—atopic dermatitis	1.51e-05	0.00024	CcSEcCtD
Pimecrolimus—Abdominal pain—Dexamethasone—atopic dermatitis	1.51e-05	0.00024	CcSEcCtD
Pimecrolimus—Abdominal pain—Betamethasone—atopic dermatitis	1.51e-05	0.00024	CcSEcCtD
Pimecrolimus—Body temperature increased—Dexamethasone—atopic dermatitis	1.51e-05	0.00024	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IL5—atopic dermatitis	1.5e-05	0.000874	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Prednisone—atopic dermatitis	1.49e-05	0.000237	CcSEcCtD
Pimecrolimus—MTOR—DAP12 interactions—IL6—atopic dermatitis	1.49e-05	0.000867	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—atopic dermatitis	1.49e-05	0.000867	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	1.49e-05	0.000867	CbGpPWpGaD
Pimecrolimus—Pruritus—Triamcinolone—atopic dermatitis	1.49e-05	0.000237	CcSEcCtD
Pimecrolimus—Pruritus—Methylprednisolone—atopic dermatitis	1.49e-05	0.000236	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—atopic dermatitis	1.48e-05	0.00086	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL10—atopic dermatitis	1.47e-05	0.000857	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—atopic dermatitis	1.47e-05	0.000852	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—atopic dermatitis	1.46e-05	0.000848	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKBIA—atopic dermatitis	1.45e-05	0.000841	CbGpPWpGaD
Pimecrolimus—Rash—Prednisolone—atopic dermatitis	1.44e-05	0.000229	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisolone—atopic dermatitis	1.44e-05	0.000229	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—CMA1—atopic dermatitis	1.44e-05	0.000837	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL11—atopic dermatitis	1.44e-05	0.000837	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Methylprednisolone—atopic dermatitis	1.44e-05	0.000228	CcSEcCtD
Pimecrolimus—MTOR—Immune System—TLR2—atopic dermatitis	1.43e-05	0.000834	CbGpPWpGaD
Pimecrolimus—Headache—Prednisolone—atopic dermatitis	1.43e-05	0.000228	CcSEcCtD
Pimecrolimus—Constipation—Prednisone—atopic dermatitis	1.42e-05	0.000226	CcSEcCtD
Pimecrolimus—Vomiting—Hydrocortisone—atopic dermatitis	1.42e-05	0.000226	CcSEcCtD
Pimecrolimus—Rash—Hydrocortisone—atopic dermatitis	1.41e-05	0.000224	CcSEcCtD
Pimecrolimus—Dermatitis—Hydrocortisone—atopic dermatitis	1.41e-05	0.000224	CcSEcCtD
Pimecrolimus—Headache—Hydrocortisone—atopic dermatitis	1.4e-05	0.000222	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—NFKBIA—atopic dermatitis	1.39e-05	0.000808	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Prednisone—atopic dermatitis	1.36e-05	0.000216	CcSEcCtD
Pimecrolimus—Nausea—Prednisolone—atopic dermatitis	1.36e-05	0.000216	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—STAT6—atopic dermatitis	1.35e-05	0.000787	CbGpPWpGaD
Pimecrolimus—Pruritus—Betamethasone—atopic dermatitis	1.35e-05	0.000215	CcSEcCtD
Pimecrolimus—Pruritus—Dexamethasone—atopic dermatitis	1.35e-05	0.000215	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CD79A—atopic dermatitis	1.35e-05	0.000784	CbGpPWpGaD
Pimecrolimus—Vomiting—Triamcinolone—atopic dermatitis	1.34e-05	0.000213	CcSEcCtD
Pimecrolimus—Vomiting—Methylprednisolone—atopic dermatitis	1.34e-05	0.000212	CcSEcCtD
Pimecrolimus—Nausea—Hydrocortisone—atopic dermatitis	1.33e-05	0.000211	CcSEcCtD
Pimecrolimus—Rash—Triamcinolone—atopic dermatitis	1.33e-05	0.000211	CcSEcCtD
Pimecrolimus—Dermatitis—Triamcinolone—atopic dermatitis	1.33e-05	0.000211	CcSEcCtD
Pimecrolimus—Rash—Methylprednisolone—atopic dermatitis	1.32e-05	0.00021	CcSEcCtD
Pimecrolimus—Dermatitis—Methylprednisolone—atopic dermatitis	1.32e-05	0.00021	CcSEcCtD
Pimecrolimus—Urticaria—Prednisone—atopic dermatitis	1.32e-05	0.00021	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	1.32e-05	0.000768	CbGpPWpGaD
Pimecrolimus—Headache—Triamcinolone—atopic dermatitis	1.32e-05	0.000209	CcSEcCtD
Pimecrolimus—Headache—Methylprednisolone—atopic dermatitis	1.32e-05	0.000209	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—atopic dermatitis	1.31e-05	0.000209	CcSEcCtD
Pimecrolimus—Body temperature increased—Prednisone—atopic dermatitis	1.31e-05	0.000209	CcSEcCtD
Pimecrolimus—Diarrhoea—Dexamethasone—atopic dermatitis	1.31e-05	0.000208	CcSEcCtD
Pimecrolimus—Diarrhoea—Betamethasone—atopic dermatitis	1.31e-05	0.000208	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—CASP8—atopic dermatitis	1.3e-05	0.000759	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL5—atopic dermatitis	1.27e-05	0.000738	CbGpPWpGaD
Pimecrolimus—Nausea—Triamcinolone—atopic dermatitis	1.25e-05	0.000199	CcSEcCtD
Pimecrolimus—Nausea—Methylprednisolone—atopic dermatitis	1.25e-05	0.000198	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisone—atopic dermatitis	1.23e-05	0.000195	CcSEcCtD
Pimecrolimus—Vomiting—Betamethasone—atopic dermatitis	1.21e-05	0.000193	CcSEcCtD
Pimecrolimus—Vomiting—Dexamethasone—atopic dermatitis	1.21e-05	0.000193	CcSEcCtD
Pimecrolimus—Rash—Dexamethasone—atopic dermatitis	1.2e-05	0.000191	CcSEcCtD
Pimecrolimus—Rash—Betamethasone—atopic dermatitis	1.2e-05	0.000191	CcSEcCtD
Pimecrolimus—Dermatitis—Dexamethasone—atopic dermatitis	1.2e-05	0.000191	CcSEcCtD
Pimecrolimus—Dermatitis—Betamethasone—atopic dermatitis	1.2e-05	0.000191	CcSEcCtD
Pimecrolimus—Headache—Dexamethasone—atopic dermatitis	1.2e-05	0.00019	CcSEcCtD
Pimecrolimus—Headache—Betamethasone—atopic dermatitis	1.2e-05	0.00019	CcSEcCtD
Pimecrolimus—Pruritus—Prednisone—atopic dermatitis	1.18e-05	0.000187	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—NGF—atopic dermatitis	1.17e-05	0.000683	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR3—atopic dermatitis	1.17e-05	0.000682	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR5—atopic dermatitis	1.14e-05	0.000664	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Prednisone—atopic dermatitis	1.14e-05	0.000181	CcSEcCtD
Pimecrolimus—Nausea—Betamethasone—atopic dermatitis	1.13e-05	0.00018	CcSEcCtD
Pimecrolimus—Nausea—Dexamethasone—atopic dermatitis	1.13e-05	0.00018	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IL18—atopic dermatitis	1.1e-05	0.000642	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—atopic dermatitis	1.09e-05	0.000632	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—atopic dermatitis	1.08e-05	0.00063	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—atopic dermatitis	1.07e-05	0.000623	CbGpPWpGaD
Pimecrolimus—Vomiting—Prednisone—atopic dermatitis	1.06e-05	0.000168	CcSEcCtD
Pimecrolimus—Rash—Prednisone—atopic dermatitis	1.05e-05	0.000167	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—atopic dermatitis	1.05e-05	0.000166	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—TAC1—atopic dermatitis	1.05e-05	0.000608	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NPS—atopic dermatitis	1.05e-05	0.000608	CbGpPWpGaD
Pimecrolimus—Headache—Prednisone—atopic dermatitis	1.04e-05	0.000166	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—atopic dermatitis	1.03e-05	0.000598	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR3—atopic dermatitis	1.03e-05	0.000596	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—atopic dermatitis	1.02e-05	0.000596	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—atopic dermatitis	1.02e-05	0.000591	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisone—atopic dermatitis	9.88e-06	0.000157	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—IL5—atopic dermatitis	9.72e-06	0.000565	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKBIA—atopic dermatitis	9.69e-06	0.000563	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCR5—atopic dermatitis	9.18e-06	0.000534	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK8—atopic dermatitis	9.08e-06	0.000528	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFKBIA—atopic dermatitis	8.43e-06	0.00049	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL10—atopic dermatitis	8.29e-06	0.000482	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—atopic dermatitis	7.6e-06	0.000442	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL5—atopic dermatitis	7.13e-06	0.000415	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—atopic dermatitis	6.91e-06	0.000402	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGF—atopic dermatitis	6.61e-06	0.000384	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—atopic dermatitis	6.6e-06	0.000384	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—atopic dermatitis	6.46e-06	0.000376	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR5—atopic dermatitis	6.43e-06	0.000374	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—atopic dermatitis	6.24e-06	0.000363	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK8—atopic dermatitis	6.08e-06	0.000353	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLB1—atopic dermatitis	6.02e-06	0.00035	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—atopic dermatitis	5.8e-06	0.000337	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADSL—atopic dermatitis	5.77e-06	0.000336	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—atopic dermatitis	5.76e-06	0.000335	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—atopic dermatitis	5.76e-06	0.000335	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—atopic dermatitis	5.74e-06	0.000334	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—atopic dermatitis	5.54e-06	0.000322	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKBIA—atopic dermatitis	5.45e-06	0.000317	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK8—atopic dermatitis	5.29e-06	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—atopic dermatitis	3.89e-06	0.000226	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—atopic dermatitis	3.88e-06	0.000226	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—atopic dermatitis	3.71e-06	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK8—atopic dermatitis	3.42e-06	0.000199	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—atopic dermatitis	3.38e-06	0.000196	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—atopic dermatitis	3.12e-06	0.000181	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—atopic dermatitis	2.18e-06	0.000127	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARA—atopic dermatitis	1.95e-06	0.000114	CbGpPWpGaD
